Avinger (NSDQ:AVGR), which earlier this month launched a new version of its Pantheris peripheral atherectomy device, registered for the sale of up to $50 million worth of its stock. Redwood City, Calif.-based Avinger said the deal with Cowen & Co. doesn’t oblige it to sell any shares. Last week the company said it would immediately launch an […]
Peripheral
Boston Scientific wins CE Mark for Eluvia peripheral stent
Boston Scientific (NYSE:BSX) said today that it won CE Mark approval in the European Union for its Eluvia peripheral vessel stent for above-the-knee procedures. Marlborough, Mass.-based Boston Scientific said it plans to immediately begin commercializing the Eluvia drug-eluting stent in Europe and other nations that recognize the mark. The paclitaxel-coated Eluvia stent is indicated for treating lesions […]
Medtronic touts In.Pact Admiral DCB data
Medtronic (NYSE:MDT) today touted data from a pair of studies of its In.Pact Admiral drug-coated balloon, presented today at the annual Vascular Interventional Advances conference in Las Vegas. Researchers revealed the formal cost-effectiveness analysis of the U.S. cohort of Medtronic’s In.Pact SFA trial, and in-stent restenosis cohort data from its In.Pact Global study. Medtronic said the 2-year, […]
TCT 2015: More 2-year data on Bard’s Lutonix DEB
C.R. Bard (NYSE:BCR) yesterday released 2-year results from a small group of patients in a real-world registry study of its Lutonix drug-eluting balloon at the annual Transcatheter Cardiovascular Therapeutics conference in San Franscisco. Bard said the Lutonix 035 device, which is designed to treat peripheral artery disease, showed a 94.3% rate of freedom from target lesion revascularization in […]
PAD: Intact Vascular wins IDE for Tack endo repair
Intact Vascular said today it won FDA Investigative Device Exemption for a clinical trial of its Tack endovascular system for patients with peripheral arterial disease undergoing percutaneous angioplasty. The Tack endovascular system is designed to repair dissections that occur as a complication of balloon angioplasty. The system allows operating physicians to repair dissections with only […]
PAD: Boston Scientific touts Eluvia trial data
Boston Scientific (NYSE:BSX) said today that a 12-month study of its Eluvia drug-eluting stent reported a primary patency of 96%, which the company claims is the highest reported for a femoropopliteal artery lesion treatment for patients with peripheral artery disease. The palitaxel-coated Eluvia stent is the 1st stent designed to be deployed in the superficial femoral […]
Avinger pulls in $55m term loan
Avinger said it won a $55 million term loan and securities purchase agreement with CRG. The Redwood City, Calif.-based company took out $30 million initially with interest paid over 4 years. CRG purchased $5 million in shares from Avinger along with the loan. “We are pleased to support Avinger in achieving its growth plans and […]
Hansen Medical pulls the trigger on 1-for-10 reverse stock split
Hansen Medical (NSDQ:HNSN) this week pulled the trigger on a reverse 10-for-1 stock split in which HNSN shareholders received 1 share for every 10 they owned. The reverse split went into effect Sept. 22, according to a regulatory filing, sending HNSN shares down -13% to $4.35 apiece. The stock was trading at $4.26 per share in […]
Penumbra clears $125m in IPO
Penumbra (NYSE:PEN) yesterday said the net proceeds from its just-closed initial public offering were roughly $124.5 million, including an underwriters over-allotment worth $18 million. Alameda, Calif.-based Penumbra floated 4.6 million shares at $30 apiece, for gross proceeds of $138 million. PEN shares opened at $40 each Sept. 18, peaking at $42 in their 1st day of […]
Penumbra prices $120 million initial public offering
Penumbra priced its initial public offering today, saying it plans to raise $120 million by floating 4 million shares at $30 apiece. The company is also offering a 30-day underwriters option for an additional 600,000 shares. Penumbra shares are slated to trade on the New York Stock Exchange today under the “PEN” symbol. When Alameda, Calif.-based Penumbra registered the IPO last […]
Penumbra sets terms for $101m IPO
Penumbra today set the range for its pending initial public offering, saying it plans to float 3.8 million shares at $25 to $28 apiece. That works out to a range of $95 million to $106.4 million, $100.7 million at the midpoint. When Alameda, Calif.-based Penumbra registered the IPO last month it estimated the offering could fetch as […]